Comparative Pharmacology
Head-to-head clinical analysis: BYDUREON versus BYETTA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BYDUREON versus BYETTA.
BYDUREON vs BYETTA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Glucagon-like peptide-1 (GLP-1) receptor agonist; increases insulin secretion, decreases glucagon secretion, slows gastric emptying, and promotes satiety.
Exenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist that enhances glucose-dependent insulin secretion, suppresses glucagon secretion, slows gastric emptying, and promotes satiety.
2 mg subcutaneously once every 7 days (weekly).
5 mcg subcutaneously twice daily within 60 minutes before morning and evening meals; may increase to 10 mcg twice daily after 1 month if tolerated.
None Documented
None Documented
Terminal elimination half-life is approximately 2.4 hours after subcutaneous administration for immediate-release exenatide; however, BYDUREON (extended-release) exhibits a prolonged half-life of approximately 2 weeks (mean range 14-20 days) due to encapsulation in microspheres.
Terminal elimination half-life 2.4 hours; provides clinical duration of action supporting twice-daily dosing.
Excreted primarily via renal proteolytic degradation; intact exenatide is eliminated renally. Renal clearance accounts for approximately 80% of total clearance; fecal elimination is negligible (<5%).
Primarily renal; intact drug eliminated in urine (approximately 80% of the dose). Minor biliary/fecal excretion accounts for <10%.
Category C
Category C
Antidiabetic
Antidiabetic